Novartis AG Sponsored ADR (NVS)
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs
The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European pharmaceutical giants said in a letter published in the Financial Times on Wednesday.
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum?
NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and Fabhalta.
Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat
Novartis plans to expand its current manufacturing, research and technology presence in the United States following Trump's announcement of tariffs on pharmaceutical imports.
Novartis Plans $23B Investment in US Facilities as Trump Threatens Pharma Tariffs
Swiss pharmaceutical giant Novartis (NVS) said it plans to invest $23 billion in the construction and expansion of 10 U.S. facilities, as drugmakers brace for potential tariffs from the Trump administration.
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats
Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump administration.
Novartis After Sandoz: The Business Without Generics
Novartis has restructured to focus solely on innovative branded drugs, showing double-digit growth in revenue and profit in 2024. The company is strong in oncology, cardiology, immunology, and neurology, with key drugs like Entresto, Cosentyx, Kisqali, and Pluvicto driving growth. Novartis plans to grow by 5% annually, aiming for a 40% operating margin and up to 20 new molecule approvals by 2030.
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.
Novartis (NVS) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes?
Here's Why Novartis (NVS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 glomerulopathy.
Novartis Reports Updated Positive Data From Phase III SMA Program
NVS reports new safety and efficacy data from the phase III program for its investigational OAV101 IT gene therapy for SMA patients.
